{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:15:37Z","timestamp":1775600137516,"version":"3.50.1"},"reference-count":128,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:15:22Z","timestamp":1749755722000},"page":"474-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-1939","authenticated-orcid":false,"given":"Krishnan R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon P.","family":"Basourakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah E.","family":"Citrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.semradonc.2025.04.001_bib0001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.001_bib0003","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijrobp.2020.07.2194","article-title":"An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high-and intermediate-risk prostate cancer","volume":"108","author":"Oh","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0004","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.prro.2024.06.006","article-title":"Target volume optimization for localized prostate cancer","volume":"14","author":"Patel","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"10338","key":"10.1016\/j.semradonc.2025.04.001_bib0005","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): An international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.001_bib0007","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.01.022","article-title":"The benefit of short-term androgen deprivation therapy with radiation therapy for intermediate-risk prostate cancer","author":"Patel","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0009","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer research"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0010","first-page":"134","article-title":"Inhibition of human mammary and prostatic cancers by adrenalectomy","volume":"12","author":"Huggins","year":"1952","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0011","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in oncology: prostate Cancer (version 1.2025). Accessed January 1, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: Principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","article-title":"Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer","volume":"14","author":"Deville","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/21681805.2022.2094462","article-title":"The Swedish national guidelines on prostate cancer, part 1: Early detection, diagnostics, staging, patient support and primary management of non-metastatic disease","volume":"56","author":"Bratt","year":"2022","journal-title":"Scand J Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.semradonc.2025.04.001_bib0016","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9660","key":"10.1016\/j.semradonc.2025.04.001_bib0017","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/pr.55.1.3","article-title":"Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands","volume":"55","author":"Hauger","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0019","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fendo.2017.00274","article-title":"Gonadotropin-releasing hormone (GnRH) receptor structure and GnRH binding","volume":"8","author":"Flanagan","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mce.2017.10.015","article-title":"Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression","volume":"463","author":"Stamatiades","year":"2018","journal-title":"Mol Cel Endocrinol"},{"issue":"23","key":"10.1016\/j.semradonc.2025.04.001_bib0021","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0022","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline. Part III: Principles of radiation and Future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.10.017","article-title":"Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: A combined analysis of the NRG oncology\/RTOG 9202, 9413, and 9902 phase 3 trials","author":"Patel","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0024","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2021.08.031","article-title":"Adding short-term androgen deprivation therapy to radiation therapy in men with localized prostate cancer: Long-term update of the NRG\/RTOG 9408 randomized clinical trial","volume":"112","author":"Jones","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15083","article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: A secondary analysis of the RTOG 9408 randomized clinical trial","volume":"3","author":"Zumsteg","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.001_bib0027","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/cncr.28609","article-title":"The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease","volume":"120","author":"Keane","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0028","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ijrobp.2009.06.038","article-title":"Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: A postrandomization analysis by risk group","volume":"77","author":"Nguyen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.001_bib0029","first-page":"289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"Jama"},{"issue":"18","key":"10.1016\/j.semradonc.2025.04.001_bib0030","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1200\/JCO.2007.15.9699","article-title":"Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy","volume":"26","author":"D'Amico","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.001_bib0031","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.2015.8577","article-title":"Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"314","author":"D\u2019Amico","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.001_bib0032","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial","volume":"292","author":"D'Amico","year":"2004","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0033","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0034","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"21","key":"10.1016\/j.semradonc.2025.04.001_bib0035","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92\u201302","volume":"21","author":"Hanks","year":"2003","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.001_bib0036","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9327","key":"10.1016\/j.semradonc.2025.04.001_bib0037","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0038","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.001_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.001_bib0040","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0041","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.001_bib0042","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/oncolo\/oyad099","article-title":"Relugolix in clinical practice: The best route for all?","volume":"28","author":"Cordes","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0043","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jval.2021.04.172","article-title":"PCN80 Estimating the difference in annual out-of-pocket costs for relugolix and leuprolide for medicare patients with metastatic prostate cancer","volume":"24","author":"Borrelli","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0044","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): A pooled analysis of five randomized trials from the meta-analysis of randomized trials in cancer of the prostate (MARCAP) consortium","volume":"87","author":"Ong","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2021.12.005","article-title":"An expert review on the combination of Relugolix with definitive radiation therapy for prostate cancer","volume":"113","author":"Roy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.semradonc.2025.04.001_bib0046","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of Degarelix versus leuprolide in patients with prostate cancer: The primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0047","unstructured":"National Library of Medicine (US) A comparison of Orgovyx (Relugolix) vs Eligard (Leuprolide) on cardiovascular function and biomarkers during standard of care combined ADT (Androgen Deprivation Therapy)-radiation for prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT06330805. Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0048","unstructured":"National Library of Medicine (US) Mechanism and predictors of cardiotoxicity after prostate cancer treatment: a parallel cohort and randomized trial comparing radiation alone, radiation plus leuprolide, and radiation plus relugolix. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT05320406 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0049","unstructured":"National Library of Medicine (US) Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02799706 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2666-1683(24)01124-8","article-title":"O05 Irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist vs. GnRH agonist in patients with very high risk localized or locally advanced prostate cancer: the EORTC GUCG-1414 phase III PEGASUS randomized trial","volume":"69","author":"Zilli","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"28","key":"10.1016\/j.semradonc.2025.04.001_bib0051","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0052","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.19.6.1073","article-title":"Gynecomastia with ketoconazole","volume":"19","author":"DeFelice","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0053","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.juro.2007.08.011","article-title":"Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: Effect of extent of disease on outcome","volume":"178","author":"Ryan","year":"2007","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.semradonc.2025.04.001_bib0054","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/1078-0432.CCR-09-1722","article-title":"Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer","volume":"15","author":"Taplin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0055","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0056","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0057","doi-asserted-by":"crossref","unstructured":"Fizazi K., Tran N., Fein L., et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 377(4):352-360. doi:10.1056\/NEJMoa1704174","DOI":"10.1056\/NEJMoa1704174"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0058","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.semradonc.2025.04.001_bib0059","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0060","unstructured":"FDA. ZYTIGA (abiraterone acetate) tablets. Accessed March 20, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202379lbl.pdf"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.001_bib0061","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2020.11.059","article-title":"Combination of radiation therapy and short-term androgen blockade with abiraterone acetate plus prednisone for men with high- and intermediate-risk localized prostate cancer","volume":"109","author":"Koontz","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: a multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0063","unstructured":"National Library of Medicine (US) Risk stratified de-escalated de-intensified treatment for high Risk prostate cancer patients based on pathologic criteria, genetic score, and biologic imaging. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT06369610. Accessed February 12, 2024."},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.001_bib0064","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: Final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10336","key":"10.1016\/j.semradonc.2025.04.001_bib0065","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"10467","key":"10.1016\/j.semradonc.2025.04.001_bib0066","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"10323","key":"10.1016\/j.semradonc.2025.04.001_bib0067","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"10162","key":"10.1016\/j.semradonc.2025.04.001_bib0068","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.001_bib0069","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0070","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: A secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.001_bib0072","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.001_bib0073","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv268","article-title":"Androgen deprivation therapy-linked cardiovascular disease risk: still unresolved","volume":"107","author":"Azvolinsky","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0075","unstructured":"National Library of Medicine (US) A prospective, randomized, open-label, multi-centre, phase II trial evaluating IDC\/SChLAP1 as a biomarker for prediction of response to intensified combined modality treatment. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04176081.Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0076","unstructured":"National Library of Medicine (US) Parallel phase III randomized trials of genomic-risk stratified unfavorable intermediate risk prostate cancer: de-intensification and intensification clinical trial evaluation (GUIDANCE). National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT05050084 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0077","unstructured":"National Library of Medicine (US) Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in intermediate and limited high risk localized prostate cancer: A phase III study. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03488810 Accessed February 12, 2024."},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0078","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS349","article-title":"A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15)","volume":"42","author":"Roubaud","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0079","article-title":"Short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: The Darius (AFU-GETUG P15) Phase 2 trial protocol","author":"Sargos","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS384","article-title":"INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer","volume":"38","author":"King","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891886","article-title":"Phase II study of ENZAlutamide combined with hypofractionated radiation therapy (ENZART) for localized intermediate risk prostate cancer","volume":"12","author":"Lara","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0082","unstructured":"National Library of Medicine (US) Enzalutamide with external beam radiation for intermediate risk prostate cancer: A phase II study. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02028988 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0083","unstructured":"National Library of Medicine (US) DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801): A randomised phase 3 double-blind, placebo-controlled trial of adding Darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04136353. Accessed February 12, 2024."},{"issue":"15_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0084","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5087","article-title":"ATLAS: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","volume":"34","author":"Sandler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.001_bib0085","article-title":"Addition of enzalutamide to leuprolide and definitive radiation therapy is tolerable and effective in high-risk localized or regional nonmetastatic prostate cancer: Results from a phase 2 trial","volume":"7","author":"Shee","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0086","unstructured":"National Library of Medicine (US) Treatment of high-risk prostate cancer guided by novel diagnostic radio- and molecular tracers (THUNDER): a two-part phase 2\/3 trial. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT06282588 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0087","unstructured":"National Library of Medicine (US) Parallel phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation (PREDICT-RT*). National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04513717 Accessed February 12, 2024."},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0088","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5127","article-title":"ALADDIN: evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases","volume":"42","author":"Oudard","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0089","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.131","article-title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: initial results from RTOG 3506 (STEEL)","volume":"42","author":"Posadas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0091","unstructured":"National Library of Medicine (US) A phase II, double-blinded, Placebo controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with Apalutamide in recurrent prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03371719 Accessed February 12, 2024."},{"issue":"15_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0092","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5100","article-title":"Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa)","volume":"36","author":"McBride","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5012","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0094","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.ijrobp.2024.07.088","article-title":"Long-term patient-reported health-related quality of life in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either Bicalutamide or Abiraterone acetate plus prednisone and Apalutamide after radical prostatectomy","volume":"120","author":"Hoffman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.001_bib0095","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.semradonc.2025.04.001_bib0096","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.21.00596","article-title":"Radiation and androgen deprivation therapy with or without docetaxel in the management of nonmetastatic unfavorable-risk prostate cancer: A prospective randomized trial","volume":"39","author":"D'Amico","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0097","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.adro.2015.11.001","article-title":"A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy","volume":"1","author":"Jackson","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.001_bib0098","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0099","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2019.08.010","article-title":"Docetaxel versus surveillance after radical radiotherapy for intermediate- or high-risk prostate cancer-results from the prospective, randomised, open-label phase III SPCG-13 trial","volume":"76","author":"Kellokumpu-Lehtinen","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2023.04.024","article-title":"Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: Long-term follow-up from the randomized NRG Oncology RTOG 0521 trial","volume":"84","author":"Sartor","year":"2023","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.semradonc.2025.04.001_bib0101","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with Docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0102","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2015.05.024","article-title":"A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: Final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902","volume":"93","author":"Rosenthal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5094","article-title":"Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology\/RTOG 0521 phase III trial","volume":"41","author":"Phillips","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0104","unstructured":"National Library of Medicine (US) A randomized phase III, factorial design, of Cabazitaxel and Pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT01952223 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0105","unstructured":"National Library of Medicine (US) Phase 2\/3 study of dose-escalated external beam radiation therapy with or without chemotherapy for high risk adenocarcinoma of the prostate. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT01603420 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: A living interactive systematic review and meta-analysis","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.001_bib0107","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.semradonc.2010.06.001","article-title":"Poly(ADP-Ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets","volume":"20","author":"Chalmers","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0108","unstructured":"National Library of Medicine (US) A multi-center trial of androgen suppression with abiraterone aCetate, LEuprolide, PARP inhibition and stereotactic body radiotherapy (ASCLEPIuS): A phase I\/2 trial in high risk and node positive prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04194554 Accessed February 12, 2024."},{"issue":"5_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.387","article-title":"Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results","volume":"43","author":"Jackson","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0110","unstructured":"National Library of Medicine (US) Randomized phase II trial of Niraparib with standard combination radiotherapy and androgen deprivation therapy (ADT) in high risk prostate cancer (With Initial Phase I). National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04037254 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0111","unstructured":"National Library of Medicine (US) Phase II trial of primary radiotherapy with androgen ablation with or without adjuvant niraparib for selected high-risk locoregional prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04947254 Accessed February 12, 2024."},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0112","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS351","article-title":"Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer","volume":"42","author":"Myint","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0113","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28643","article-title":"Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens","volume":"3","author":"Gameiro","year":"2014","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.001_bib0114","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.001_bib0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of Ipilimumab versus Placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0116","article-title":"Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer","volume":"19","author":"Twardowski","year":"2019","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.001_bib0117","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized phase II study evaluating the addition of Pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.001_bib0118","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0119","unstructured":"National Library of Medicine (US) Combination of Nivolumab immunotherapy with radiation therapy and androgen deprivation therapy in the management of Gleason group 5 prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03543189 Accessed February 12, 2024."},{"issue":"6_suppl","key":"10.1016\/j.semradonc.2025.04.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS212","article-title":"Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer","volume":"40","author":"Grabbert","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0121","unstructured":"National Library of Medicine (US) A phase II study evaluating T-cell clonality after stereotactic body radiation therapy alone and in combination with the immunocytokine M9241 in localized high and intermediate risk prostate cancer treated with androgen deprivation therapy. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT05361798 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0122","unstructured":"National Library of Medicine (US) Open-label, phase 2 clinical trial of pre-radiation and post-radiation immunotherapy with N-803, ETBX-071, and M-CENK in combination with radiation for participants with high-risk prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT06765954 Accessed February 12, 2024."},{"key":"10.1016\/j.semradonc.2025.04.001_bib0123","unstructured":"National Library of Medicine (US) A randomized controlled trial of ProstAtak\u00ae as adjuvant to up-front radiation therapy for localized prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT01436968 Accessed February 12, 2024."},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.001_bib0124","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1200\/JCO.21.02742","article-title":"FDA approval summary: Abemaciclib with endocrine therapy for high-risk early breast cancer","volume":"40","author":"Royce","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.001_bib0125","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-23-3436","article-title":"A signal-finding study of Abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1","volume":"30","author":"Agarwal","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.001_bib0126","unstructured":"National Library of Medicine (US) Phase II clinical trial of Abemaciclib in combination with androgen deprivation therapy for locally advanced prostate cancer. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04298983 Accessed February 12, 2024."},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.001_bib0127","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/1008-682X.122876","article-title":"PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance","volume":"16","author":"Edlind","year":"2014","journal-title":"Asian J Androl"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.001_bib0128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2016.10.013","article-title":"Phase 1 trial of Everolimus and radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy","volume":"97","author":"Narayan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:16:30Z","timestamp":1762355790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000293"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.001","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}